Navigation Links
Interfering with interferon
Date:7/28/2014

Using the body's natural virus killers to prevent and treat HIV infection has been problematic until now because of the strong inflammatory response these molecules can arouse as they get rid of the invaders. Now, collaborative research conducted by scientists at the Weizmann Institute and the National Institutes of Health (NIH) have demonstrated how suppressing the activity of these molecules interferons around the time of infection could have long-term implications for the course of the disease. Their research appeared in Nature.

Interferons, named for their ability to "interfere" with viral replication, protect us against disease, but they are also the source of inflammation when we are sick. Today, interferons are used to treat such viral diseases as hepatitis. But in HIV, it has been thought that the inflammation and other side effects could be too harmful and the danger of a "runaway" immune response too great. Prof. Gideon Schreiber of the Weizmann Institute's Biological Chemistry Department and team, including postdoctoral fellow Dr. Doron Levin and former postdoc Dr. Ganit Yarden, had, in previous research, designed an antagonist molecule that is able to block some of the activities of interferons while still allowing them to proceed to act against viruses.

Their original motivation, says Schrieber, was to better understand the mechanisms of different versions of the interferon molecule. This research revealed that the activity of each interferon is tuned to specific cells and viruses. The molecule they had created, says Schrieber, "was not a true 'antagonist' in the biological sense: Instead of blocking all IFN activity, it was able to target the mechanisms leading to the prevention of replication and modulation of the immune system, leaving the antiviral activity mostly intact."

Next, Schrieber and his group teamed up with Dr. Netanya Sandler and Prof. Daniel Douek at the NIH to understand what happens when full-out interferon activity is tampered with in HIV. The research was done on simian immunodeficiency virus (SIV) the animal equivalent to HIV. Their results show that the actions blocked by the molecule may have important functions, even if they appear to be "detrimental." The team administered an antagonist, blocking a IFN for the first four weeks after infection. Even after this short period, they found that the natural immune system activities did not recover and compensate to the level they otherwise would have; and this led to a progression of the disease.

Schreiber: "These results clearly demonstrate the importance of an early, general IFN response in fighting HIV infection, and removing the 'harmful' IFN functions even for just a short period at the onset of infection can have devastating and permanent consequences in shaping the course of disease." Taken together, these findings suggest that not only the type of treatment, but also the timing of IFN administration needs to be considered in the management and prevention of disease.


'/>"/>

Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert  

Related biology news :

1. New data suggests interferon-free therapy around the corner for HCV patients
2. Height, weight and BMI changes seen in children treated with peginterferon alpha for hepatitis C
3. Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Interfering with interferon
(Date:2/3/2016)... DUBLIN , Feb. 3, 2016 /PRNewswire/ ... announced the addition of the "Emotion ... NLP, Machine Learning, and Others), Software Tools ... Application Areas, End Users,and Regions - Global ... offering. --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... New FDA action date of July 22, 2016 ... 22, 2016   --> - New ... - Lifitegrast has the potential to be the only product ... signs and symptoms of dry eye disease in adults --> ... in the U.S. in the past decade indicated for the treatment of signs ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology: